Form 4: United Therapeutics EVP Executes Stock Option Plan

EVP and General Counsel Paul A. Mahon exercised 8,300 stock options and sold the resulting shares under a 10b5-1 trading plan.

Summary

• Paul A. Mahon, EVP and General Counsel of United Therapeutics, exercised 8,300 stock options at a strike price of $146.03.
• Following the exercise, the reporting person sold the 8,300 shares in multiple transactions at weighted average prices ranging from $539.76 to $549.49 per share.
• The transactions were conducted pursuant to a Rule 10b5-1 trading plan established on August 11, 2025.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as it represents a routine, pre-planned executive transaction rather than a fundamental shift in company operations.

Positives

• The transaction was pre-planned under a Rule 10b5-1 plan, indicating the sale was not based on non-public information.
• The exercise of options demonstrates long-term alignment with the company's equity performance.

Negatives

• The transaction results in a reduction of the executive's direct beneficial ownership of common stock.

Risks

• None identified; this is a routine executive compensation-related transaction.

Future Outlook

No forward-looking guidance provided; this is a disclosure of past executive transactions.

Industry Context

StockSavvy.ai notes that routine 10b5-1 sales by high-level executives are standard practice in the biotechnology sector for liquidity and tax planning purposes and generally do not signal a change in corporate strategy.

Comparison to Industry Standards

• The use of 10b5-1 plans is the industry standard for corporate officers to mitigate insider trading concerns.
• The volume of shares sold represents a small fraction of the executive's total holdings, consistent with typical executive compensation liquidation patterns.

Stakeholder Impact

• Minimal impact on shareholders as the transaction was pre-arranged and executed via a 10b5-1 plan.

Next Steps

• No further actions required by the company regarding this specific filing.

Key Dates

Keywords

United Therapeutics, UTHR, Insider Trading, Form 4, Stock Options, 10b5-1